Amneal Pharmaceuticals, Inc. - News - Press Releases

2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Dec 13, 2012

Impax Laboratories Names Bryan M. Reasons as Chief Financial Officer

Nov 21, 2012

Impax Laboratories Enters Into Development, Manufacturing and Commercialization Agreement with Perrigo

Nov 20, 2012

Impax Laboratories to Present at the Piper Jaffray 24th Annual Healthcare Conference

Nov 16, 2012

Impax Laboratories and ThoRx Laboratories Confirm Patent Challenge Relating to Generic OPANA® ER 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 40 mg

Nov 08, 2012

Impax Laboratories to Present at the Credit Suisse 2012 Healthcare Conference

Oct 30, 2012

Impax Laboratories Reports Third Quarter 2012 Results

Oct 12, 2012

Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date to January 21, 2013

Oct 10, 2012

Impax Laboratories Announces Time Change for Third Quarter 2012 Earnings Conference Call on October 30

Oct 09, 2012

Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2012 Financial Results

Sep 17, 2012

Impax Laboratories to Present at the UBS Global Life Sciences Conference

Sep 14, 2012

Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA®

Sep 04, 2012

Impax Laboratories Announces Settlement of Litigation Relating to RENVELA® and RENAGEL®

Jul 31, 2012

Impax Laboratories Reports Second Quarter 2012 Adjusted EPS Increased to $0.60; GAAP EPS Increased to $0.27

Jul 10, 2012

Impax Laboratories Schedules Conference Call and Webcast for Second Quarter 2012 Financial Results

Jun 29, 2012

Impax Laboratories Announces Resignation of Arthur A. Koch

Jun 26, 2012

Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.

Jun 14, 2012

Impax Laboratories to Present at the Wells Fargo Securities Healthcare Conference

Jun 06, 2012

Amneal Upgrades Generic Metformin Family by Listening to Customers

Jun 04, 2012

Impax Laboratories to Present at the Goldman Sachs Annual Global Healthcare Conference

May 22, 2012

Impax Laboratories Announces Voting Results from 2012 Annual Meeting of Stockholders

May 15, 2012

Amneal Pharmaceuticals Bucks Trend and Adds U.S. Manufacturing Jobs with Major Expansion

May 10, 2012

Impax Laboratories to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

May 01, 2012

Impax Laboratories Reports Adjusted First Quarter 2012 EPS of $0.52; GAAP EPS of $0.18

Apr 18, 2012

Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference

Apr 12, 2012

Impax Laboratories Confirms Patent Challenge Relating to Generic GRALISE® 300 mg and 600 mg

Apr 04, 2012

Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2012 Financial Results

Mar 26, 2012

Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.

Mar 14, 2012

Amneal Launches Escitalopram Oxalate Oral Solution

Mar 01, 2012

Impax Laboratories to Present at the Cowen and Company Health Care Conference

Feb 28, 2012

Impax Laboratories Fourth Quarter 2011 EPS Increases 74% to $0.33

Feb 24, 2012

Impax Laboratories to Present at the RBC Capital Markets’ Healthcare Conference

Feb 23, 2012

FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease

Feb 13, 2012

Amneal Pharmaceuticals CEO Kicks Off 2012 HIA-LI CEO Roundtable Series

Feb 09, 2012

Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility

Feb 01, 2012

Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights to Zomig® (zolmitriptan) from AstraZeneca

Jan 26, 2012

Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2011 Financial Results

Jan 04, 2012

Impax Laboratories to Present at the J.P. Morgan Healthcare Conference

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.15.0.14